唑来膦酸联合不同剂量姑息放疗治疗乳腺癌骨转移

目的 探讨放疗联合唑来膦酸治疗乳腺癌骨转移的安全性及有效性.方法 乳腺癌骨转移患者随机分为高剂量和低剂量放疗组,从放疗开始,所有患者均接受唑来膦酸(4 mg),28 d一周期共6周期.VAS评分和全身骨扫描用来评价治疗效果.结果 两组放疗后疼痛评分、累积不良骨事件发生率,及骨扫描结果无明显差别.结论 联合唑来膦酸,高剂量放疗和低剂量放疗治疗乳腺癌骨转移,二者疗效相当,但低剂量组治疗时间短,并发症较少.

Oledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases

【Objective】 In this prospective study,the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.【Methods】 Breast cancer patients with painful bone metastases were randomized to either high-or reduced-dose radiotherapy.All patients received zoledronic acid(4 mg) every 28 days from the beginning of radiotherapy.Analgesic and pain scores in addition to visual analog score(VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated.【Results】 No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups.【Conclusion】 Reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid,but outputs complications.